There are numerous published studies on the subject, including using pharmacologic intratumoral delivery of vectors encoding FasL (195), a variety of tumor vaccine approaches that activate molecular pattern receptors (196–198), applications of CAR-T cell immunotherapies (199), and others (200, 201). Here, FASLG is linked to neoplasm.